Michael Kleinmann, DO
Nephrology · Mobile, ALNPI 1386620912
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $44,135 of the $50,268 with a category attached, or 87.8%. 28 manufacturers reported payments, led by Bayer at 58.3% of the total. Reporting peaked in 2022 at $21,699 and has fallen 97.5% since, to $533 in 2025. Among nephrology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 257 payments — averaging $195.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$29K
- Otsuka America Pharmaceutical, Inc.$13K
- Amgen$5K
- AstraZeneca$769
- Bard Peripheral Vascular, Inc.$356
- Aurinia Pharma U.S., Inc.$180
- plus $1K from 22 others
What the payments were for
- Speaking & faculty fees$44,13588%
- Travel & lodging$2961%
- Food & beverage$5,76811%
- Education$690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 34 | $29,287 |
| Otsuka America Pharmaceutical, Inc. | 36 | $13,314 |
| Amgen(2 entities) | 81 | $4,907 |
| AstraZeneca(2 entities) | 35 | $769 |
| Bard Peripheral Vascular, Inc. | 6 | $356 |
| Aurinia Pharma U.S., Inc. | 6 | $180 |
| Nxstage Medical, Inc. | 2 | $180 |
| Novartis | 7 | $173 |
| Calliditas Therapeutics US Inc. | 6 | $120 |
| Vifor Pharma, Inc. | 7 | $120 |
| Boston Scientific | 1 | $120 |
| Akebia Therapeutics Inc | 6 | $114 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $106 |
| OPKO Pharmaceuticals, LLC | 4 | $66 |
| Fresenius USA Marketing, Inc. | 4 | $61 |
| Daiichi Sankyo Inc. | 2 | $46 |
| GSK | 3 | $45 |
| Medtronic | 3 | $43 |
| Johnson & Johnson | 2 | $41 |
| Mallinckrodt Hospital Products Inc. | 1 | $40 |
| Lilly USA, LLC | 2 | $38 |
| W. L. Gore & Associates, Inc. | 1 | $27 |
| Davol Inc. | 1 | $26 |
| Mozarc Medical US LLC | 1 | $23 |
| Lemaitre Vascular, Inc. | 1 | $20 |
| Convatec Inc. | 1 | $18 |
| Apellis Pharmaceuticals, Inc. | 1 | $17 |
| Bioventus LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$50,268 in reported general payments places this provider in the 90th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 13 | $246,071 |
| FarxigaDapagliflozin Propanediol | 210 | $172,921 |
| KerendiaFinerenone | 128 | $93,593 |
| JardianceEmpagliflozin | 97 | $89,657 |
| MounjaroTirzepatide | 39 | $50,299 |
| OzempicSemaglutide | 30 | $28,225 |
| VascepaIcosapent Ethyl | 11 | $3,669 |
| Potassium Citrate ErPotassium Citrate | 15 | $2,327 |
| Allopurinol | 191 | $2,100 |
| Febuxostat | 11 | $1,481 |
| Ezetimibe | 88 | $1,302 |
| Chlorthalidone | 69 | $1,110 |
| Mycophenolate Mofetil | 12 | $988 |
| Losartan Potassium | 106 | $868 |
| Tamsulosin Hcl | 33 | $716 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $13,314 | $246,07113 claims |
| AstraZenecaFarxiga | $769 | $172,921210 claims |
| BayerKerendia | $29,287 | $93,593128 claims |
| Lilly USA, LLCMounjaro | $38 | $50,29939 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 164 nephrology providers in Alabama.
Other nephrology in Mobile
- Andrew FelisMobile$35K
- Douglas AmareMobile$10K
- Roy CulpepperMobile$5K
- Purnima TripathyMobile$5K
- Christopher MireMobile$5K
- Richard MeadorMobile$4K
- John NipperMobile$4K
- Errol CrookMobile$4K
- Stephen WilberMobile$4K
- Michael QuadriniHuntsville$323K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.